Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery
JAMA · 01.09.2026 · 336 (9) · 765
DOI: 10.1001/jama.2026.9268 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 01.09.2026. Verfasst von Maartina J P Oosterom-Eijmael und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Acute Kidney Injury, Benzhydryl Compounds, Cardiac Surgical Procedures, Glucosides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Two percent to 50% of patients undergoing elective cardiac surgery experience acute kidney injury (AKI) postoperatively. Medications to prevent AKI after elective cardiac surgery have not been identified.
Objective
In patients undergoing elective cardiac surgery, to evaluate whether initiating dapagliflozin 1 day prior to surgery reduces the incidence of AKI at 7 days after cardiac surgery, compared with placebo. Design, Setting, and Participants Multicenter, double-blind, placebo-controlled randomized clinical trial conducted at 2 academic medical centers and 5 nonacademic hospitals in the Netherlands. Eligible participants were adults undergoing elective cardiac surgery. Enrollment occurred between June 8, 2023, and January 27, 2025. Final follow-up occurred May 16, 2025.
Intervention
Patients were randomized 1:1 to receive either dapagliflozin (10 mg orally; n = 392) or placebo once daily (n = 392), beginning on the day before surgery and continuing through the second postoperative day (total of 4 doses). Main Outcome and Measure The primary outcome was the between-group difference in AKI (defined as an increase in serum creatinine level by at least 0.3 mg/dL [26.5 µmol/L] within 48 hours after surgery, a 1.5-fold creatinine increase within 7 days of surgery, or urine output less than 0.5 mL/kg/h for 6 to 12 hours according to Kidney Disease: Improving Global Outcomes criteria) during the first 7 postoperative days.
Results
Of 784 participants enrolled, 778 (99%) completed follow-up testing (median age, 68 [61-74] years; 76% male; 97% White; median body mass index, 27 [IQR, 25-30]; and median estimated glomerular filtration rate, 80 [IQR, 67-89] mL/min/1.73 m 2 ). Compared with placebo, dapagliflozin reduced the incidence of AKI (28% vs 52%; relative risk, 0.54 [95% CI, 0.45-0.65]; P < .001) over 7-day follow-up after surgery. Atrial fibrillation and reoperation were the most frequent adverse events. The incidence of atrial fibrillation was 45% (176/392) in the dapagliflozin group vs 45% (176/392) in the placebo group, and the incidence of reoperation was 11% (43/392) vs 10% (39/392), respectively. Conclusions and Relevance In patients undergoing elective cardiac surgery, 4 doses of dapagliflozin, beginning the day before surgery, reduced the incidence of AKI during the 7-day postoperative period. Trial Registration ClinicalTrials.gov Identifier: NCT05590143
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
- Department of Endocrinology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
- Amsterdam Cardiovascular Sciences Research Institute, Amsterdam, the Netherlands.
- Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam, the Netherlands.
- Department of Anesthesiology, Medisch Spectrum Twente, Enschede, the Netherlands.
- Department of Anesthesiology and Intensive Care, Amphia Hospital, Breda, the Netherlands.
Zitieren
APA
Oosterom-Eijmael, M. J. P., Hulst, A. H., de Oliveira, N. P. M., Niesten, E. D., Wietsma, N. E., Gerritse, B. M., Scohy, T. V., Rettig, T. C. D., Snellen, F. T. F., Voogd, M. F., Godfried, M. B., de Boer, R. N., Wink, J., van der Werff, L. M. M., Cobbaert, C. M., Ruhaak, L. R., Eberl, S., Preckel, B., Hollmann, M. W., …, & MERCURI-2 Study Group (2026). Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery. JAMA, 336(9), 765. https://doi.org/10.1001/jama.2026.9268
Vancouver
Oosterom-Eijmael MJP, Hulst AH, de Oliveira NPM, Niesten ED, Wietsma NE, Gerritse BM, et al. Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery. JAMA. 2026;336(9):765. doi:10.1001/jama.2026.9268
BibTeX
@article{OosteromEijmael2026,
author = {Oosterom-Eijmael, Maartina J P and Hulst, Abraham H and de Oliveira, Nelson P Monteiro and Niesten, Ed D and Wietsma, Nicobert E and Gerritse, Bastiaan M and Scohy, Thierry V and Rettig, Thijs C D and Snellen, Ferdinand T F and Voogd, Magiel F and Godfried, Marc B and de Boer, Rients N and Wink, Jeroen and van der Werff, Lisa M M and Cobbaert, Christa M and Ruhaak, L Renee and Eberl, Susanne and Preckel, Benedikt and Hollmann, Markus W and Schenk, Jimmy and Hermanides, Jeroen and van Raalte, Daniel H and MERCURI-2 Study Group, MERCURI-2 Study Group},
title = {Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery},
journal = {JAMA},
year = {2026},
volume = {336},
number = {9},
pages = {765},
doi = {10.1001/jama.2026.9268}
}
EUVIMED